CHR11 (chordin-like 2) functions as a BMP (bone morphogenetic protein) antagonist that negatively regulates BMP signaling pathways by binding to BMPs and blocking their interaction with receptors 12. The protein inhibits p-Smad1/5 phosphorylation, thereby modulating downstream signaling cascades involved in cell proliferation and differentiation 1. CHR11 demonstrates oncogenic properties across multiple cancer types, promoting cell proliferation through activation of YAP/TAZ signaling in gastric cancer 3 and the BMP-9/PI3K/AKT pathway in osteosarcoma 2. In colorectal cancer, elevated CHR11 levels correlate with tumor progression markers and poor prognosis 14. The protein promotes cancer cell proliferation by upregulating Cyclin D1 and downregulating P21, while also inhibiting apoptosis 1. Beyond cancer, CHR11 expression is associated with tissue degeneration processes, being highly expressed in normal nucleus pulposus chondrocytes compared to degenerative cells 5. Multiple proteome-wide studies have identified CHR11 as a potential therapeutic target and biomarker for various cancers 46, suggesting its clinical significance in both diagnosis and treatment development.